Disc Medicine (IRON) Long-Term Investments (2020)
Disc Medicine (IRON) posted quarterly Long-Term Investments of $120.8 million for Q4 2020, little changed quarter-over-quarter from $120.8 million in Q3 2020.
Powered by 
Analysis
Disc Medicine (IRON) Long-Term Investments (2020) Analysis & Trends
Disc Medicine (IRON) has reported Long-Term Investments for 1 consecutive years, with $120.8 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Long-Term Investments changed N/A year-over-year to $120.8 million; the TTM figure through Dec 2020 stood at $120.8 million (changed N/A YoY), while the FY2020 annual figure was $120.8 million, changed N/A from the prior year.
- Long-Term Investments held at $120.8 million in Q4 2020 per IRON's latest filing, from $120.8 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $120.8 million in Q3 2020 and bottomed at $120.8 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Disc Medicine | 3.08 Bn | 3.08 Bn | - | - |